Please assess the completion status of the following clinical trial:

Trial Title: Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subject participated in the preceding placebo-controlled Phase 3 study ANB019-301 and completed at least the Week 1 visit of the ANB019-301 study without the use of rescue/prohibited medication for GPP~* Subject must be a candidate for prolonged GPP treatment according to the Investigator's judgment~Exclusion Criteria:~* Use of prohibited medications between the last visit of the ANB019-301 study and the Day 1 visit of the ANB019-302 study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IV +SC Imsidolimab (Type: ACTIVE_COMPARATOR): IV loading dose followed by subcutaneous Imsidolimab
- SC Imsidolimab (Type: ACTIVE_COMPARATOR): Subcutaneous Imsidolimab
- SC Placebo (Type: PLACEBO_COMPARATOR): Subcutaneous Placebo
- Standard of Care (Type: NO_INTERVENTION): Any available therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).